Affinia readies its engineered AAVs for the clinic with $110M B round led by crossovers EcoR1, Farallon

Money continues to pour into companies working on the next-generation of AAV vectors, with Affinia’s $110 million, crossover-heavy series B round for Affinia the latest raise. 

Led by EcoR1 Capital and Farallon Capital Management, the new round builds on a $60 million series A round led by F-Prime Capital, New Enterprise Associates and Atlas Venture announced last March, and a deal with Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced the next month that brought Affinia Therapeutics $80 million in upfront and near-term milestone payments...